AstraZeneca Extends RSV Deal With Aussie Biotech Biota
This article was originally published in PharmAsia News
PERTH, Australia - Melbourne-based Biota's 2005 antiviral collaboration and license agreement with MedImmune has been picked up by AstraZeneca and expanded to include a number of Asian territories, Biota announced Aug. 25
You may also be interested in...
Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31
AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 2 of 2)
AstraZeneca's Head of R&D in Asia Patrick Keohane sat down recently with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).